COMMUNIQUÉS West-GlobeNewswire

Nanox Engages with Althea France to Accelerate European Commercialization of Nanox.ARC System
25/11/2025
Althea France, part of one of Europe's largest independent medical technology services provider s , to distribute CE-marked Nanox.ARC system across French healthcare sector Partnership represents Nanox's fourth European [...]
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
25/11/2025
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP ) , the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access [...]
Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS
25/11/2025
Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. ( [...]
LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment
25/11/2025
Located at the Daresbury site of the renowned UK-based Science and Technology Facilities Council (STFC), with $300+ million invested to date in developing the technology BOCA RATON, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Anticipates Major Fair-Value Uptick Following New Independent JV Valuation
25/11/2025
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
25/11/2025
Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX₁₀₀ PETACH TIKVA, Israel, [...]
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences
25/11/2025
THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual [...]
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
25/11/2025
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its [...]
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
25/11/2025
Company to advance care through broader access to breadth of skin substitutes across four unique technology platforms PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq [...]
Xenon to Present New Azetukalner OLE Study Data in Epilepsy at AES 2025
25/11/2025
Seven posters to be presented, including new X-TOLE OLE data supporting the ability to attain and regain extended periods of seizure freedom with long-term use of azetukalner Data will also highlight the impact of [...]
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
25/11/2025
Live webcast fireside chat on Thursday, December 4 th at 10:30 AM ET Carlsbad, CA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical [...]
Prenetics Announces Upcoming Conference Participation
25/11/2025
CHARLOTTE, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today [...]
Foundation for Sarcoidosis Research Convenes Global Leaders for Landmark Clinic Alliance Meeting and Sarcoidosis Biomarker Summit
25/11/2025
CHICAGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) brought together more than 40 leading clinicians and researchers from around the world for two landmark events: the inaugural in- [...]
BioStem Technologies Expands Product Access in Medicaid
25/11/2025
Florida Medicaid Adds BioStem’s VENDAJE® and VENDAJE AC® to Covered Skin Substitutes List POMPANO BEACH, Fla., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company [...]
Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease
25/11/2025
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage [...]
Adalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase of Growth in AI-driven Speech-based Biomarkers and Behavioural Analytics for Optimising Clinical Trials
25/11/2025
ESPOO, Finland, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Adalyon, a pioneering tech-bio company using its AI-powered speech biomarker platform to transform clinical drug development, today announced the appointment of Ulrik [...]
Zelluna ASA – Extraordinary General Meeting held on November 25, 2025
25/11/2025
Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s [...]
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée
25/11/2025
Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing [...]
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
25/11/2025
Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and [...]

Pages